<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172195</url>
  </required_header>
  <id_info>
    <org_study_id>1708033</org_study_id>
    <secondary_id>ANSM</secondary_id>
    <nct_id>NCT03172195</nct_id>
  </id_info>
  <brief_title>Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up</brief_title>
  <acronym>VIRCH</acronym>
  <official_title>Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Flare-up of ulcerative colitis (UC) is characterized by the inflammation of colon mucosa that&#xD;
      requires the use of immunosuppressive therapies. In previous studies, the active role of&#xD;
      cytomegalovirus (CMV) has been demonstrated, with a correlation between the cytomegalovirus&#xD;
      DNA ((deoxyribonucleic acid) load in the inflamed tissue and the resistance to successive&#xD;
      lines of immunosuppressive therapy (Roblin et al., Am J Gastroenterol 2011). The main aim of&#xD;
      this monocentric prospective study is to evaluate the DNA viral load by qPCR (Polymerase&#xD;
      Chain Reaction) of 3 herpesviruses (Epstein-Barr virus, herpes virus 6 and herpes simplex)&#xD;
      together with that of CMV in colonic mucosa depending of the local inflammation&#xD;
      (endoscopically normal region, inflamed mucosa or ulcer) in patients suffering of moderate to&#xD;
      severe UC flare-up (Mayo score &gt;6 with endoscopic score higher or equal than 2). The viral&#xD;
      load will also be correlated to the Mayo endoscopic score and the response to&#xD;
      immunosuppressive drugs (steroid and anti-TNF (Tumor Necrosis Factor) monoclonal antibodies).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with different viral load in the colonic mucosa</measure>
    <time_frame>day 1</time_frame>
    <description>Different viral loads are a composite outcome : viral load of CMV, EBV, HHV-6 and HSV.&#xD;
It will be measured by Polymerase Chain Reaction technical in colonic mucosa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of the different viral loads with the Mayo endoscopic score</measure>
    <time_frame>Day 1</time_frame>
    <description>Different viral loads are a composite outcome : viral load of CMV, EBV, HHV-6 and HSV.&#xD;
It will be measured by Polymerase Chain Reaction technical in colonic mucosa The Mayo endoscopic score integrate the severity from lesions of colonic mucosa measured by rectosigmoidoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the different viral loads with the steroid treatment response</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Different viral loads are a composite outcome : viral load of CMV, EBV, HHV-6 and HSV.&#xD;
It will be measured by Polymerase Chain Reaction technical in colonic mucosa.&#xD;
Steroid treatment response is defined by clinic mayo score &lt; 3 measured by rectosigmoidoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the different viral loads with the anti-TNF treatment response</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Different viral loads are a composite outcome : viral load of CMV, EBV, HHV-6 and HSV.&#xD;
It will be measured by Polymerase Chain Reaction technical in colonic mucosa. anti-TNF treatment response is defined by clinic mayo score &lt; 3 measured by rectosigmoidoscopy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Patients with ulcerative colitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>rectosigmoidoscopy</intervention_name>
    <description>A rectosigmoidoscopy will be realized and two fragments will be collected.</description>
    <arm_group_label>Patients with ulcerative colitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>biopsies</intervention_name>
    <description>For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.</description>
    <arm_group_label>Patients with ulcerative colitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Blood sample will be collected in more.</description>
    <arm_group_label>Patients with ulcerative colitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18 years&#xD;
&#xD;
          -  Voluntary to participate to the study&#xD;
&#xD;
          -  Flare-up of ulcerative colitis with Mayo score &gt;6&#xD;
&#xD;
          -  Ability to receive steroid or anti-TNF therapy&#xD;
&#xD;
          -  Agree the rectosigmoidoscopy and the therapies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Disagree the rectosigmoidoscopy or the therapies&#xD;
&#xD;
          -  Participation to the evaluation of a new therapy&#xD;
&#xD;
          -  Colectomy (partial or total)&#xD;
&#xD;
          -  Contraindication of steroid or anti-TNF therapy&#xD;
&#xD;
          -  Anticoagulant drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Roblin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier Roblin, MD PhD</last_name>
    <phone>(0)477828119</phone>
    <phone_ext>+33</phone_ext>
    <email>xavier.roblin@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence RANCON, CRA</last_name>
    <phone>(0)477829458</phone>
    <phone_ext>+33</phone_ext>
    <email>florence.rancon@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier ROBLIN, MD PhD</last_name>
      <phone>(0)477828119</phone>
      <phone_ext>+33</phone_ext>
      <email>xavier.roblin@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie DEL TEDESCO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier ROBLIN, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas WILLIET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie PILLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno POZZETTO, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline VEYRARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ulcerative colitis</keyword>
  <keyword>inflammation</keyword>
  <keyword>immunosuppressive drugs</keyword>
  <keyword>herpesvirus</keyword>
  <keyword>qPCR</keyword>
  <keyword>colonic mucosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

